摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-fluorobenzenesulfonate | 1621574-90-0

中文名称
——
中文别名
——
英文名称
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-fluorobenzenesulfonate
英文别名
(6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-3-yl) 4-fluorobenzenesulfonate
6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-fluorobenzenesulfonate化学式
CAS
1621574-90-0
化学式
C20H17FO5S
mdl
——
分子量
388.416
InChiKey
BGFQQUWPIHKHKK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.97
  • 重原子数:
    27.0
  • 可旋转键数:
    3.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    73.58
  • 氢给体数:
    0.0
  • 氢受体数:
    5.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    环庚酮硫酸 、 sodium hydride 、 三乙胺三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 4.0h, 生成 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-fluorobenzenesulfonate
    参考文献:
    名称:
    新型三环和四环稠合香豆素磺酸盐衍生物的合成及其对 RAW 264.7 巨噬细胞中 LPS 诱导的一氧化氮和 PGE2 产生的抑制作用:第 2 部分
    摘要:
    描述了一系列新的 21 种融合香豆素衍生物的合成,以及它们作为脂多糖 (LPS) 诱导的一氧化氮 (NO) 和前列腺素 E2 (PGE2) 在 RAW 264.7 巨噬细胞中产生的抑制剂的体外抗炎作用的生物学评价。首先测试目标化合物 1a-u 的细胞毒性,以确定用于抗炎筛选的无毒浓度,因此对 NO 和 PGE2 产生的抑制作用不会由细胞毒性引起。化合物 1f 和 1p 是活性最强的 PGE2 抑制剂,IC50 值分别为 0.89 和 0.95 µM。蛋白质印迹和无细胞 COX-2 筛选表明,它们的作用是由于抑制了 COX-2 蛋白表达和 COX-2 酶活性。它们对 COX-2 酶的 IC50 值分别为 0.67 和 0.85 µM,这比依托考昔更有效。与COX-1相比,化合物1f和1p对COX-2的选择性指数分别为41.1和42.5。化合物 1f 在 5 µM 浓度下对 LPS 诱导的 RAW
    DOI:
    10.1002/ardp.201600243
点击查看最新优质反应信息

文献信息

  • Tricyclic coumarin sulphonate derivatives with alkaline phosphatase inhibitory effects: <i>in vitro</i> and docking studies
    作者:Jamshed Iqbal、Mohammed I. El-Gamal、Syeda Abida Ejaz、Joanna Lecka、Jean Sévigny、Chang-Hyun Oh
    DOI:10.1080/14756366.2018.1428193
    日期:2018.1.1
    tricyclic coumarin sulphonate 1a-za with known antiproliferative activity, was evaluated for AP inhibition against human tissue nonspecific alkaline phosphatase (h-TNAP) and human intestinal alkaline phosphatase (h-IAP). The methylbenzenesulphonate derivative 1f (IC50 = 0.38 ± 0.01 μM) was found to be the most active h-TNAP inhibitor. Another 4-fluorobenzenesulphonate derivative 1i (IC50 = 0.45 ± 0
    组织非特异性碱性磷酸酶(TNAP)是碱性磷酸酶的重要同工酶,在人体中起着不同的关键作用。最重要的是,它负责维持磷酸盐和无机焦磷酸盐的平衡比例,从而在骨骼形成和生长过程中调节细胞外基质化。TNAP平升高与血管化和晚期肾脏疾病有关。因此,需要寻找强效​​和选择性的碱性磷酸酶(AP)抑制剂以治疗与AP过表达相关的疾病。在这里,一系列具有已知抗增殖活性的三环香豆素磺酸盐1a-za,评估AP对人组织非特异性碱性磷酸酶(h-TNAP)和人肠碱性磷酸酶(h-IAP)的抑制作用。发现甲基苯磺酸生物1f(IC50 = 0.38±0.01μM)是最具活性的h-TNAP抑制剂。发现另一种4-氟苯磺酸盐衍生物1i(IC50 = 0.45±0.02μM)是h-IAP的最强抑制剂。一些衍生物也被鉴定为AP的高选择性抑制剂。研究了详细的结构-活性关系(SAR),以鉴定负责有效抑制AP同工酶的官能团。该研究还受
  • Synthesis, in vitro antiproliferative activity, and in silico studies of fused tricyclic coumarin sulfonate derivatives
    作者:Mohammed I. El-Gamal、Chang-Hyun Oh
    DOI:10.1016/j.ejmech.2014.06.064
    日期:2014.9
    A series of fused tricyclic coumarin sulfonate derivatives was synthesized. Their in vitro antiproliferative activities against a panel of 57 human cancer cell lines of nine different cancer types were tested at the NCI. Compounds 1e, 1f, 1h, 1i, and 1o showed the highest mean percentage of inhibition values over the 57 cell line panel at 10 μM, and they were further tested in 5-dose testing mode to determine their IC50 values. Compounds 1e, 1f, and 1o were more selective against leukemia and colon cancer subpanels, while compounds 1h and 1i showed broad-spectrum anticancer activities. Compounds 1e, 1f, 1h, 1i, and 1o demonstrated high selectivity towards cancer cell lines than RAW 264.7 macrophages. Compound 1h exerted lethal effect over NCI-H522 NSCLC, SK-MEL-5 melanoma, and A498 renal cancer cell lines with percentage of inhibition values of 114.10%, 103.23%, and 100.52% at 10 μM concentration, respectively. Moreover, the IC50 value of compound 1o against HT29 colon cancer cell line was 532 nM. Compounds 1e, 1f, 1h, 1i, and 1o were tested for inhibitory effect over cyclooxygenase-2 (COX-2) enzyme as a possible mechanism of action. Furthermore, in silico studies were conducted to check the compliance of those five compounds with Lipinski's rule of five, and hence estimate their oral bioavailability.
查看更多

同类化合物

3-羟基-8,9,10,11-四氢-7H-环庚基色烯-6-酮 2-(3,4-亚甲二氧基苯基)环庚三烯并[b]吡喃-4,9-二酮 irosustat 2,4-dibromo-3-hydroxy-7,8,9,10-tetrahydro-benzo[c]chromen-6-one 2-phenyl-4H-thiopyrano[3,2-b]quinoline-4-one 3-pinacolatoboro-6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c][1]benzopyran 8-Phenyl-6,7-dihydro-8H-5-oxa-dibenzo[a,h]azulene 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-fluorobenzenesulfonate 2-(2-bromophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 3-[(trifluoromethylsulfonyl)oxy]-6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c][1]benzopyran 3-hydroxy-2-(3-methyl-butyl)-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one 6,7-dimethoxy-1-methyl-2-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)-3,4-dihydroisoquinolin-2-ium bromide 2-butyl-3-hydroxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one Irosustat metabolite M17 3-methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one syn-1,2,3,4,5,6,10,11,12,13,14,15-dodecahydro-2,6-methano-11,15-methanodicycloocta<1,4,7>dioxaselenocine-1,10,18,19-tetraone (1S,8R,9R,12R)-10-Oxo-1,8-diphenyl-11-oxa-tricyclo[7.2.1.02,7]dodeca-2(7),3,5-triene-12-carboxylic acid methyl ester 3-Hydroxy-2-(4-dimethylaminophenyl)-4,9-dihydrocycloheptapyran-4,9-dione 5-Brom-3-aethoxycarbonyl-7-methyl-8-hydroxy-1-oxa-azulan-2-on 3-(tert-butyl-dimethyl-silanyloxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one 2-(3-nitrophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 3,4-dimethoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one 3-oxo-9,10-dihydro-3H-2-oxa-phenanthrene-1-carboxylic acid tert-butylamide 2-(2-chlorophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 6-bromo-2-(2-methoxyphenyl)-8-methylchromen-4-one 3,9-diamino-1,7-di[1',3'-dihydro-2'H-indol-2-one spiro]naphtho[2,1-6:6,5-6']dipyran-2,8-dicabonitrile 3-Chloro-4-diethylamino-5,6-dihydro-furo[2,3-h]chromen-2-one 3-[[3-(Chloromethyl)phenyl]cyclopropylmethyl]-5,6,7,8,9,10-hexahydro-4-hydroxy-2H-cycloocta[b]pyran-2-one 4-(Methyl-phenyl-amino)-3-phenyl-6,7-dihydro-5H-1-oxa-dibenzo[a,c]cyclohepten-2-one (E)-2-Amino-4,5-dihydro-4-oxo-indeno<1,2-b>pyran-3-carbaldoxim 3-Phenyl-4-pyrrolidin-1-yl-6,7-dihydro-5H-1-oxa-dibenzo[a,c]cyclohepten-2-one 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-(tert-butyl)benzenesulfonate 4-(5-(1H-imidazol-1-yl)-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-amino-7-hydroxy-8-methyl-4H-chromene-3-carbonitrile 2-oxo-3-phenyl-2,6-dihydro-[1,3]oxazino[2,3-a]isoindol-5-ium-4-olate 1-butanoyl-7-butoxy-5-methoxy-7-phenyl-8-oxabenzo[c]bicyclo[3.2.1]octan-2-one 3-(4-iodophenyl)-4-(2-oxopropyl)-2-phenyl-3,4-dihydro-5H-chromeno[3,4-c]pyridin-5-one 2-(3,5-dichlorophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 2-(2,5-dimethoxyphenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 2-(4-bromophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyran-2-one N-ethyl-3-hydroxy-N,N-dimethyl-5-{4-[(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy]butoxy}benzenaminium iodide Eschenmoser's α-pyrone 6-bromo-2-(2-bromophenyl)cyclohepta[b]pyran-4,9-dione 3-(7-[2,2']bithienyl-5-yl-2,3-dihydro-[1,4]thiazepin-5-yl)-4-hydroxy-6-methyl-pyran-2-one isobellendine 6,7,8,9-tetrahydro-4-hydroxy-3-(1-phenylpropyl)cycloheptapyran-2(5H)-one isatropolone C 6,8-Dibromo-2-(2-methoxyphenyl)cyclohepta[b]pyran-4,9-dione 13-Amino-11-(4-fluorophenyl)-3,5-dimethyl-7-oxo-4,14-dioxatricyclo[8.4.0.02,6]tetradeca-1(10),2,5,8,12-pentaene-12-carbonitrile